EcoDrugPlus

Histone Deacetylase 8

Ensembl ID : ENSLCAG00010024272
Gene Symbol: HDAC8
1 Cross references
205 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSLCAG00010008292
Gene Symbol: HCN4
1 Cross references
212 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSLCAG00010018761
Gene Symbol: HCN4
1 Cross references
221 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSLCAG00010027798
Gene Symbol: LOC108892395
4 Cross references
203 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSLCAG00010002901
Gene Symbol: IKBKB
1 Cross references
199 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSLCAG00010011836
Gene Symbol: INPP5D
1 Cross references
215 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSLCAG00010016069
Gene Symbol: INSRA
4 Cross references
212 Possible Orthologues:

Insulin Receptor B

Ensembl ID : ENSLCAG00010024130
Gene Symbol: INSRB
4 Cross references
212 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSLCAG00010007343
Gene Symbol: IGF1RA
4 Cross references
204 Possible Orthologues:

Insulin-Like Growth Factor 1b Receptor

Ensembl ID : ENSLCAG00010026927
Gene Symbol: IGF1RB
4 Cross references
203 Possible Orthologues:

Integrin Beta 3b

Ensembl ID : ENSLCAG00010003410
Gene Symbol: ITGB3B
1 Cross references
194 Possible Orthologues:

Integrin Beta-1

Ensembl ID : ENSLCAG00010005380
Gene Symbol: LOC108880947
4 Cross references
228 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).